tirzepatide affect sleep Eli Lilly's gained FDA approval in December 2024 for treating moderate-to-severe obstructive apnea in adults with obesity, after Phase III trials showed a 20% average weight loss and a roughly 😴 Sleep Apnea FAQ 😴

During a calorie deficit, recovery is compromised

Confirm current shipping terms before enrollment

Signs you may need to reduce dose include persistent headaches, unusual fatigue, or injection site reactions that worsen over time

Figure 4 3.4 Publication bias assessment The assessment of publication bias for key outcomes revealed mixed findings

Inflammation-Related Pathways KPV is studied for pathways involved in inflammatory signaling and may be considered in personalized wellness programs

Surgical Risk: The use of GLP-1s can slow stomach emptying, which may pose risks (e.g., aspiration) during anesthesia if the medication is not paused prior to surgery